Relief Therapeutics Holding SA (OTCMKTS:RLFTF – Get Free Report)’s stock price was up 13.9% on Monday . The company traded as high as $0.32 and last traded at $0.32. 2,175 shares were traded during trading, a decline of 45% from the average session volume of 3,966 shares. The stock had previously closed at $0.2809.
Relief Therapeutics Stock Performance
The company’s 50-day simple moving average is $0.27 and its 200-day simple moving average is $0.56.
About Relief Therapeutics
Relief Therapeutics AG is a clinical‐stage biopharmaceutical company focused on the development of novel therapies for rare and critical care indications. Headquartered in Geneva, Switzerland, the company leverages its expertise in peptide biology to address diseases with high unmet need, including acute respiratory distress syndrome (ARDS) and other serious pulmonary and inflammatory conditions.
The company’s lead product candidate, RLF‐100 (aviptadil), is a synthetic formulation of vasoactive intestinal peptide (VIP) being evaluated for the treatment of ARDS and COVID-19–associated respiratory failure.
Further Reading
- Five stocks we like better than Relief Therapeutics
- Commodities Are Booming, But These 3 ETFs Tell Different Stories
- 3 Active ETFs Making Big Moves in August
- This ETF Is Outperforming by Avoiding the S&P 500’s Biggest Problem
- Birkenstock Beats the Skeptics—But Not on EPS
Receive News & Ratings for Relief Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Relief Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
